REDWOOD CITY, Calif., May 18, 2026
Galvanize Therapeutics has announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the company’s Aliya® EX Generator, a next-generation pulsed electric field (PEF) system designed for the surgical ablation of soft tissue. The clearance significantly expands the company’s growing Aliya PEF portfolio and strengthens its position in the rapidly evolving non-thermal ablation technology market focused on oncology and chronic lung disease treatment.
The newly cleared Aliya EX Generator is designed to deliver substantially larger soft tissue ablation zones while preserving the core biologic and procedural advantages associated with Aliya PEF energy technology. According to Galvanize Therapeutics, the system can achieve up to a 2x larger ablation diameter and as much as a 7x increase in ablation volume compared with the previous-generation platform, potentially expanding treatment options for patients with larger or more complex lesions.
FDA Clearance Expands Advanced Soft Tissue Ablation Options
The FDA clearance marks a major milestone for Galvanize Therapeutics as the company continues advancing minimally invasive medical technologies capable of treating soft tissue lesions using non-thermal energy delivery. Unlike conventional thermal ablation methods that rely on heat or freezing, the Aliya EX system uses high-voltage, short-duration electrical pulses to induce non-thermal regulated cell death while preserving surrounding tissue architecture.
Industry experts believe non-thermal pulsed electric field therapies may offer important procedural advantages in interventional oncology and pulmonary medicine because they can minimize collateral tissue damage while maintaining compatibility with existing biopsy workflows and standard cancer treatment protocols.
Advertisement
The Aliya EX platform is specifically designed to address a broader range of lesion sizes and treatment scenarios. Physicians using the technology may gain increased flexibility when approaching patients who previously had limited eligibility for ablation procedures due to tumor size, location, or complexity.
Michael Pritchett, DO, MPH, Director of the Chest Center of the Carolinas at FirstHealth Moore Regional Hospital and Pinehurst Medical Clinic, stated that the expanded capabilities of Aliya EX could significantly influence multidisciplinary cancer care planning and long-term patient management strategies. The ability to vary ablation size and shape may create additional treatment pathways for patients with challenging solid tumors.
Pulsed Electric Field Technology Gains Momentum in Oncology
Pulsed electric field technology continues to emerge as one of the most promising innovations in modern interventional oncology and minimally invasive medicine. The Aliya PEF platform works by delivering controlled electrical pulses directly into targeted tissue, disrupting cellular membranes and triggering regulated cell death without the extensive thermal injury commonly associated with conventional ablation technologies.
Preclinical and early clinical research has suggested that PEF-mediated cell death may promote antigen release and potentially stimulate immune system activation, opening opportunities for integration with immunotherapy and other cancer treatment approaches. However, Galvanize Therapeutics noted that the Aliya System is not currently approved to induce immune responses for direct patient benefit.
The company emphasized that Aliya EX preserves the core biologic mechanism, procedural consistency, and workflow integration already established within the broader Aliya platform. Industry analysts believe this consistency may support easier adoption among physicians already familiar with interventional oncology and pulmonary ablation workflows.
Galvanize Expands Commercial MedTech Portfolio
Following the FDA 510(k) clearance, Galvanize Therapeutics plans to begin a limited commercial launch of the Aliya EX Generator within the United States. The company is focused on expanding applications for pulsed electric field therapies across multiple disease areas, including oncology, chronic bronchitis, cardiac arrhythmias, and other soft tissue conditions.
Galvanize Therapeutics describes itself as a commercial-stage medical technology company focused on developing biologic process-driven therapies capable of addressing significant unmet clinical needs. The company’s long-term strategy centers on advancing next-generation medical device platforms that integrate precision energy delivery with minimally invasive procedural techniques.
As healthcare providers increasingly seek safer, tissue-preserving, and workflow-compatible treatment technologies, non-thermal ablation systems such as Aliya EX are expected to play an expanding role in interventional oncology and surgical soft tissue management. The FDA clearance further positions Galvanize Therapeutics within the growing global market for advanced energy-based ablation technologies.
Source: Galvanize Therapeutics press release
